The cardiac enigma: current conundrums in heart failure research [version 1; referees: 3 approved]
The prevalence of heart failure is expected to increase almost 50% in the next 15 years because of aging of the general population, an increased frequency of comorbidities, and an improved survival following cardiac events. Conventional treatments for heart failure have remained largely static over...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
F1000 Research Ltd
2016-01-01
|
Series: | F1000Research |
Subjects: | |
Online Access: | http://f1000research.com/articles/5-72/v1 |
id |
doaj-2c72ddc31efd49d9aa026eb8bec579a8 |
---|---|
record_format |
Article |
spelling |
doaj-2c72ddc31efd49d9aa026eb8bec579a82020-11-25T04:00:13ZengF1000 Research LtdF1000Research2046-14022016-01-01510.12688/f1000research.7278.17843The cardiac enigma: current conundrums in heart failure research [version 1; referees: 3 approved]Michael S. Kapiloff0Craig A. Emter1Cardiac Signal Transduction and Cellular Biology Laboratory, Interdisciplinary Stem Cell Institute, Departments of Pediatrics and Medicine, Leonard M. Miller School of Medicine, University of Miami, Miami, FL, USADepartment of Biomedical Sciences, University of Missouri-Columbia, Columbia, MO, USAThe prevalence of heart failure is expected to increase almost 50% in the next 15 years because of aging of the general population, an increased frequency of comorbidities, and an improved survival following cardiac events. Conventional treatments for heart failure have remained largely static over the past 20 years, illustrating the pressing need for the discovery of novel therapeutic agents for this patient population. Given the heterogeneous nature of heart failure, it is important to specifically define the cellular mechanisms in the heart that drive the patient’s symptoms, particularly when considering new treatment strategies. This report highlights the latest research efforts, as well as the possible pitfalls, in cardiac disease translational research and discusses future questions and considerations needed to advance the development of new heart failure therapies. In particular, we discuss cardiac remodeling and the translation of animal work to humans and how advancements in our understanding of these concepts relative to disease are central to new discoveries that can improve cardiovascular health.http://f1000research.com/articles/5-72/v1Cardiovascular PharmacologyDrug Discovery & DesignHealth Systems & Services ResearchHeart FailureHypertensionMolecular Pharmacology |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Michael S. Kapiloff Craig A. Emter |
spellingShingle |
Michael S. Kapiloff Craig A. Emter The cardiac enigma: current conundrums in heart failure research [version 1; referees: 3 approved] F1000Research Cardiovascular Pharmacology Drug Discovery & Design Health Systems & Services Research Heart Failure Hypertension Molecular Pharmacology |
author_facet |
Michael S. Kapiloff Craig A. Emter |
author_sort |
Michael S. Kapiloff |
title |
The cardiac enigma: current conundrums in heart failure research [version 1; referees: 3 approved] |
title_short |
The cardiac enigma: current conundrums in heart failure research [version 1; referees: 3 approved] |
title_full |
The cardiac enigma: current conundrums in heart failure research [version 1; referees: 3 approved] |
title_fullStr |
The cardiac enigma: current conundrums in heart failure research [version 1; referees: 3 approved] |
title_full_unstemmed |
The cardiac enigma: current conundrums in heart failure research [version 1; referees: 3 approved] |
title_sort |
cardiac enigma: current conundrums in heart failure research [version 1; referees: 3 approved] |
publisher |
F1000 Research Ltd |
series |
F1000Research |
issn |
2046-1402 |
publishDate |
2016-01-01 |
description |
The prevalence of heart failure is expected to increase almost 50% in the next 15 years because of aging of the general population, an increased frequency of comorbidities, and an improved survival following cardiac events. Conventional treatments for heart failure have remained largely static over the past 20 years, illustrating the pressing need for the discovery of novel therapeutic agents for this patient population. Given the heterogeneous nature of heart failure, it is important to specifically define the cellular mechanisms in the heart that drive the patient’s symptoms, particularly when considering new treatment strategies. This report highlights the latest research efforts, as well as the possible pitfalls, in cardiac disease translational research and discusses future questions and considerations needed to advance the development of new heart failure therapies. In particular, we discuss cardiac remodeling and the translation of animal work to humans and how advancements in our understanding of these concepts relative to disease are central to new discoveries that can improve cardiovascular health. |
topic |
Cardiovascular Pharmacology Drug Discovery & Design Health Systems & Services Research Heart Failure Hypertension Molecular Pharmacology |
url |
http://f1000research.com/articles/5-72/v1 |
work_keys_str_mv |
AT michaelskapiloff thecardiacenigmacurrentconundrumsinheartfailureresearchversion1referees3approved AT craigaemter thecardiacenigmacurrentconundrumsinheartfailureresearchversion1referees3approved AT michaelskapiloff cardiacenigmacurrentconundrumsinheartfailureresearchversion1referees3approved AT craigaemter cardiacenigmacurrentconundrumsinheartfailureresearchversion1referees3approved |
_version_ |
1724451823725576192 |